TIC10 is primarily investigated for its potential in cancer therapy due to its ability to activate the tumor suppressor protein TRAIL (TNF-related apoptosis-inducing ligand). It promotes apoptosis in cancer cells by upregulating TRAIL receptors, making tumor cells more susceptible to immune-mediated destruction. TIC10 has shown activity across various cancer types, including glioblastoma, breast, and colon cancers, especially in models resistant to conventional treatments. Its ability to cross the blood-brain barrier enhances its utility in treating brain tumors. Research also explores its role in combination therapies to improve treatment efficacy and overcome drug resistance.